Table 3

Patient characteristics

No. of patients 44
Treatment cycles131
PSa (ECOG 0/1)26/18
Gender (M/F)25/19
Median age (range)45 (19–71)
Sites of metastasis
Lymph node/s.c.8 (18%)
Visceral36 (82%)
No. of metastatic sites
110 (25%)
214 (35%)
>216 (40%)
Prior therapy33 (75%)
XRT8 (18%)
Systemic therapy29 (66%)
IFN23 (53%)
Other biological medication8 (18%)
Chemo or IL-20
Ocular primary2 (5%)
  • a PS, performance status; XRT, radiation therapy.